Dr Adam Stoten
Adam joined Oxford University Innovation in the role of Deputy Head of Technology Transfer in 2013, with specific responsibility for commercialisation of life/medical science technologies originating from Oxford research, and for managing our partnership with OUHT. Adam has more than a decade’s experience in the pharma/biotech sector in commercial roles encompassing business development and licensing, new venture formation, product development, lobbying/advocacy and general management. Between 2010 and 2013 Adam worked as Deputy General Manager for the Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, which conducted the first ever efficacy study of a new TB vaccine in infants. Adam first worked at Oxford University Innovation between 2005 and 2010 as a Project Manager and subsequently a Team Leader in the Technology Transfer Group, successfully managing a wide range of licensing deals and spin-outs spanning therapeutics, vaccines, diagnostics, research tools and software. Prior to 2005 he worked for a biotechnology consultancy undertaking due diligence and market research projects. Adam has a 1st Class Honours degree in biology and a PhD in immunology from the University of Nottingham.